Shinji Nagai Selected Research

N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamide

1/2021	Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
1/2020	Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
1/2019	Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
1/2018	Long-term safety and efficacy of the novel β3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study.
1/2018	Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shinji Nagai Research Topics

Disease

5	Overactive Urinary Bladder (Overactive Bladder) 01/2021 - 01/2018
2	Urinary Incontinence 01/2021 - 01/2020
1	Nocturia 01/2019
1	Constipation 01/2018
1	Cystitis 01/2018
1	Infections 07/2003
1	Cross Infection (Nosocomial Infection) 07/2003

Drug/Important Bio-Agent (IBA)

5	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2021 - 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	Ophthalmic Solutions (Eye Drops)IBA 07/2003

Therapy/Procedure

1	Contact Lenses 07/2003